Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10276146 | 0.87 | NPC1 (0.46) | KMT2AKDM4EALDH1A1MEN1GAA | |
| SCHEMBL26315587 | 0.87 | KMT2A (0.43) | KMT2AKDM4EALDH1A1MEN1GAA | |
| SCHEMBL10662120 | 0.82 | HDAC1 (0.51) | KMT2AKDM4EALDH1A1MEN1GAA | |
| SCHEMBL29939457 | 0.82 | HDAC1 (0.51) | KMT2AKDM4EALDH1A1MEN1GAA | |
| SCHEMBL12868073 | 0.82 | KMT2A (0.54) | KMT2AKDM4EMEN1GAAMAPT | |
| SCHEMBL23149668 | 0.81 | ALDH1A1 (0.47) | KMT2AKDM4EALDH1A1MEN1GAA | |
| SCHEMBL30786505 | 0.81 | ALDH1A1 (0.47) | KMT2AKDM4EALDH1A1MEN1GAA | |
| SCHEMBL1474603 | 0.80 | MAPT (0.42) | KMT2AKDM4EMEN1MAPTNPC1 | |
| SCHEMBL3656932 | 0.79 | KMT2A (0.46) | KMT2AKDM4EALDH1A1MEN1GAA | |
| SCHEMBL3173315 | 0.79 | DGAT1 (0.60) | KMT2AKDM4EALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358929-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2025-07-15 | — | — | US | disclosed |
| US-20240294546-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| EP-3558318-B1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-20220153755-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-20220153755-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-11274107-B2 | NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11274107-B2 | NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200087323-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2020-03-19 | — | — | US | disclosed |
| EP-3558318-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | Cadent Therapeutics, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119374-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | CADENT THERAPEUTICS (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119374-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | CADENT THERAPEUTICS (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807650-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | KMT2A 602/4885KDM4E 1415/4885ALDH1A1 2036/4885 |
| US-11274107-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | KMT2A 602/4885KDM4E 1415/4885ALDH1A1 2036/4885 |
| US-20240294546-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | KMT2A 602/4885KDM4E 1415/4885ALDH1A1 2036/4885 |
| US-12358929-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | KMT2A 602/4885KDM4E 1415/4885ALDH1A1 2036/4885 |
| US-20200087323-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | KMT2A 602/4885KDM4E 1415/4885ALDH1A1 2036/4885 |
| US-20220153755-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | KMT2A 602/4885KDM4E 1415/4885ALDH1A1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.